Farmacia Hospitalaria y Farmacogenómica

Revuelta-Herrero, JL; Chamorro-De-Vega, E; Rodriguez-Gonzalez, CG; Alonso, R; Herranz-Alonso, A; Sanjurjo-Saez, M.

Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients

ANNALS OF PHARMACOTHERAPY. 2018; 52(1): 11-18 Nº de citas: 48 [doi:10.1177/1060028017728294]

Chamorro-de-Vega, E; Gimenez-Manzorro, A; Rodriguez-Gonzalez, CG; Escudero-Vilaplana, V; De Lorenzo-Pinto, A; Iglesias-Peinado, I; Herranz-Alonso, A; Saezon, MS.

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

Expert Opinion On Drug Safety. 2018; 17(3): 235-241 Nº de citas: 3 [doi:10.1080/14740338.2018.1424829]

De Andres, C; Garcia, MI; Goicoechea, H; Martinez-Gines, ML; Garcia-Dominguez, JM; Martin, ML; Romero-Delgado, F; Benguria, A; Sanjurjo, M; Lopez-Fernandez, LA.

Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers

PHARMACOGENOMICS JOURNAL. 2018; 18(1): 98-105 Nº de citas: 14 [doi:10.1038/tpj.2016.71]

Gonzalez, J; Quiroga, M; Escudero-Vilaplana, V; Collado-Borrell, R; Herranz-Alonso, A; Saez, MS.

Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities

Expert Opinion On Drug Safety. 2018; 17(6): 553-572 Nº de citas: 10 [doi:10.1080/14740338.2018.1477937]

Garcia-Gonzalez, X; Lopez-Tarruella, S; Garcia, MI; Gonzalez-Haba, E; Blanco, C; Salvador-Martin, S; Jerez, Y; Thomas, F; Jarama, M; Saez, MS; Martin, M; Lopez-Fernandez, LA.

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Cancer Management and Research. 2018; 10: 4517-4522 Nº de citas: 6 [doi:10.2147/CMAR.S174470]

Galve-Calvo, E; Gonzalez-Haba, E; Gostkorzewicz, J; Martinez, I; Perez-Mitru, A.

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain

ClinicoEconomics and Outcomes Research. 2018; 10: 773-790 Nº de citas: 20 [doi:10.2147/CEOR.S178934]

Mañes-Sevilla M; Marzal-Alfaro MB; Romero Jiménez R; Herranz-Alonso A; Sanchez Fresneda MN; Benedi Gonzalez J; Sanjurjo-Sáez M.

Analisis modal de fallos y efectos para mejorar la calidad en los ensayos clinicos.

Journal of Healthcare Quality Research. 2018; 33(1): 33-47 Nº de citas: 1 [doi:10.1016/j.cali.2017.12.001]

Galar, A; Valerio, M; Munoz, P; Alcala, L; Garcia-Gonzalez, X; Burillo, A; Sanjurjo, M; Grau, S; Bouza, E.

Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017; 61(10): Nº de citas: 33 [doi:10.1128/AAC.00687-17]

de Lorenzo-Pinto, A; Herranz-Alonso, A; Cuellar-Basterrechea, B; Bellon-Cano, JM; Sanjurjo-Saez, M; Bueno, H.

Clinical and Economic Impact of a Multisciplinary Intervention to Reduce Bleeding Risk in Patients With Acute Coronary Syndrome

REVISTA ESPANOLA DE CARDIOLOGIA. 2017; 70(10): 825-831 Nº de citas: 5 [doi:10.1016/j.recesp.2016.12.020]

Arrabal-Duran, P; Rodriguez-Gonzalez, CG; Chamorro-de-Vega, E; Gijon-Vidaurreta, P; Herranz-Alonso, A; Sanjurjo-Saez, M.

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96weeks

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2017; 71(8): Nº de citas: 9 [doi:10.1111/ijcp.12968]

Chamorro-de-Vega, E; Rodriguez-Gonzalez, CG; Gimenez-Manzorro, A; de Lorenzo-Pinto, A; Iglesias-Peinado, I; Herranz, A; Sanjurjo, M.

Improving pharmacotherapy outcomes in patients with hepatitis C virus; infection treated with direct-acting antivirals: The GRUviC project

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2017; 71(8): Nº de citas: 8 [doi:10.1111/ijcp.12988]

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Blanco, C; Garcia-Alfonso, P; Robles, L; Gravalos, C; Rueda, D; Martinez, J; Pachon, V; Longo, F; Martinez, V; Iglesias, I; Salvador, S; Sanjurjo, M; Lopez-Fernandez, LA.

Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity

PHARMACOGENOMICS. 2017; 18(13): 1215-1223 Nº de citas: 12 [doi:10.2217/pgs-2017-0118]

Laiseca, LB; del Castillo, BT; Jimenez, CR; Manrique-Rodriguez, S; Moreno, JP.

Downbeat nystagmus due to ranitidine in a pediatric patient

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY. 2017; 21(4): 682-684 Nº de citas: 7 [doi:10.1016/j.ejpn.2017.01.015]

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Robles, L; Gravalos, C; Garcia-Alfonso, P; Pachon, V; Longo, F; Martinez, V; Blanco, C; Iglesias, I; Sanjurjo, M; Lopez-Fernandez, LA.

Identification of new SNPs associated with severe toxicity to capecitabine

PHARMACOLOGICAL RESEARCH. 2017; 120: 133-137 Nº de citas: 45 [doi:10.1016/j.phrs.2017.03.021]

Escudero-Vilaplana, V; Ribed, A; Romero-Jimenez, RM; Herranz-Alonso, A; Sanjurjo-Saez, M.

Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents

EUROPEAN JOURNAL OF CANCER CARE. 2017; 26(3): Nº de citas: 20 [doi:10.1111/ecc.12463]

Jimenez, RMR; Navarro, CO; Compes, CC.

Polypharmacy and enteral nutrition in patients with complex chronic diseases

Nutricion Hospitalaria. 2017; 34: 57-76 Nº de citas: 12 [doi:10.20960/nh.1240]

Garcia-Lopez, I; Fuentes-Rios, JE; Manrique-Rodriguez, S; Fernandez-Llamazares, CM.

Off-label and unlicensed drug use: Results from a pilot study in a pediatric intensive care unit

ANALES DE PEDIATRIA. 2017; 86(1): 28-36 Nº de citas: 18 [doi:10.1016/j.anpedi.2016.01.026]

Manrique-Rodriguez, S; de la Rubia-Nieto, A; Garcia-Robles, JA; Goicoechea-Diezhandino, M; Gimeno-Blanes, JA; Pernia-Lopez, MS; Pellicer-Franco, C; Sanjurjo-Saez, M.

Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?

Expert Opinion on Orphan Drugs. 2016; 4(12): 1199-1206 Nº de citas: 1 [doi:10.1080/21678707.2016.1253468]